Catalyst Inks Deal To End Its 'Orphan Drug' Case
Florida-based Catalyst Pharmaceuticals Inc. has inked a deal to settle its patent case against a rival involving a drug that treats a rare autoimmune disease, ending litigation that made its way...To view the full article, register now.
Already a subscriber? Click here to view full article